# REGULUS: MRI-guided Adaptive SABR for Liver Cancers

> **NCT07223307** · PHASE2 · RECRUITING · sponsor: **Stanford University** · enrollment: 62 (estimated)

## Conditions studied

- Liver Cancer
- Intrahepatic Cholangiocarcinoma
- Liver Metastases
- HCC

## Interventions

- **RADIATION:** MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)

## Key facts

- **NCT ID:** NCT07223307
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-23
- **Primary completion:** 2030-01
- **Final completion:** 2030-01
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223307, "REGULUS: MRI-guided Adaptive SABR for Liver Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07223307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*